Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; maize starch; lactose monohydrate; hyprolose; crospovidone; microcrystalline cellulose; iron oxide red - alembic aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; crospovidone; hyprolose; maize starch; silicon dioxide - alembic aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; crospovidone; hyprolose; maize starch; silicon dioxide; magnesium stearate; microcrystalline cellulose; iron oxide red - alembic aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose monohydrate; maize starch; microcrystalline cellulose; magnesium stearate; silicon dioxide; crospovidone; colour - alembic aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; hyprolose; lactose monohydrate; silicon dioxide; microcrystalline cellulose; maize starch; iron oxide red - alembic aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; crospovidone; indigo carmine aluminium lake; hyprolose; magnesium stearate; microcrystalline cellulose; silicon dioxide; lactose monohydrate - alembic aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; hyprolose; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; iron oxide black; macrogol 400 - alembic lacosamide (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; magnesium stearate; hyprolose; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 6000; macrogol 400; indigo carmine aluminium lake - alembic lacosamide (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: crospovidone; hyprolose; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - alembic lacosamide (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; hyprolose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; macrogol 400 - alembic lacosamide (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.